Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Daptomycin

FDA-approved product (powder, intravenous), marketed as Cubicin, Cubicin Rf, Daptomycin and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Daptomycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacterial endocarditis
  • Bacteriemia
  • Endocarditis
  • Gram-positive bacterial infections
  • Infection
  • Infective endocarditis
  • Skin disease caused by bacterial infection
  • Soft Tissue Infections

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antibacterials
FDA pharmacologic class
Lipopeptide Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01XX09; FDA class Lipopeptide Antibacterial

Repurposing investigation

Daptomycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA98.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
  • E. coli48.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae50.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Daptomycin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Daptomycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Impact of Three Probabilistic Antibiotic Therapy on Digestive Microbiota and Colonization With Multi-resistant Bacteria

    NCT07058415 · start 2026-07

    Registered record
    Registry ID
    NCT07058415
    Conditions
    Osteoarticular Material Infection
    Interventions
    Stool sample 1; Stool sample 2; Stool sample 3
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-07
    Completion
    2027-05
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoarticular Material Infection
    InterventionStool sample 1; Stool sample 2; Stool sample 3
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

    NCT07376889 · start 2026-02-01

    Registered record
    Registry ID
    NCT07376889
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-02-01
    Completion
    2029-01
    Enrolment
    2,096

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionAntibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
    PhasePhase 4
    Registry statusRecruiting

  • Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial

    NCT06189885 · start 2024-08-01

    Registered record
    Registry ID
    NCT06189885
    Conditions
    Periprosthetic Joint Infection
    Interventions
    Cefazolin with Daptomycin; Cefazolin with vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-08-01
    Completion
    2026-07-31
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeriprosthetic Joint Infection
    InterventionCefazolin with Daptomycin; Cefazolin with vancomycin
    PhaseNot applicable
    Registry statusUnknown

  • Staphylococcus Aureus Network Adaptive Platform Trial

    NCT05137119 · start 2022-02-16

    Registered record
    Registry ID
    NCT05137119
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Cefazolin; Penicillin; Clindamycin; Vancomycin; Effectiveness of early switch to oral antibiotics; Whole body FDG PET/CT Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-02-16
    Completion
    2028-12-01
    Enrolment
    8,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionCefazolin; Penicillin; Clindamycin; Vancomycin +2 more
    PhasePhase 4
    Registry statusRecruiting

  • Utility Assessment of a Pharmacy-to-Dose Daptomycin

    NCT05224687 · start 2021-12-15

    Registered record
    Registry ID
    NCT05224687
    Conditions
    Antibiotics Causing Adverse Effects in Therapeutic Use
    Interventions
    Retroactive review of patient data of those receiving a dose of daptomycin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-12-15
    Completion
    2022-12-15
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntibiotics Causing Adverse Effects in Therapeutic Use
    InterventionRetroactive review of patient data of those receiving a dose of daptomycin
    PhaseNot recorded
    Registry statusUnknown

  • Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®)

    NCT04033029 · start 2021-01-01

    Registered record
    Registry ID
    NCT04033029
    Conditions
    Hemodiafiltration; Sepsis; Acute Kidney Injury
    Interventions
    Continuous venovenous hemodiafiltration with high adsorption membrane (oXiris®); Antibiotics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-01-01
    Completion
    2023-06-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemodiafiltration; Sepsis; Acute Kidney Injury
    InterventionContinuous venovenous hemodiafiltration with high adsorption membrane (oXiris®); Antibiotics
    PhaseNot recorded
    Registry statusCompleted

  • Subcutaneous Daptomycin in Healthy Volunteers (DAPTOSC)

    NCT04434300 · start 2020-10-15

    Registered record
    Registry ID
    NCT04434300
    Conditions
    Antibiotics; Subcutaneous Injection; Daptomycin
    Interventions
    Daptomycin; Daptomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-10-15
    Completion
    2021-11-15
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntibiotics; Subcutaneous Injection; Daptomycin
    InterventionDaptomycin; Daptomycin
    PhasePhase 1
    Registry statusCompleted

  • The Efficacy and Safety of Daptomycin in the Treatment of Gram-positive Bacterial Infection.

    NCT04546815 · start 2020-08-25

    Registered record
    Registry ID
    NCT04546815
    Conditions
    Antibiotic
    Interventions
    Daptomycin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-08-25
    Completion
    2022-08
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntibiotic
    InterventionDaptomycin
    PhaseNot recorded
    Registry statusUnknown

  • Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI

    NCT04298463 · start 2020-06-18

    Registered record
    Registry ID
    NCT04298463
    Conditions
    Acute Bacterial Skin and Skin Structure Infection
    Interventions
    Xydalba; vancomycin, teicoplanin or daptomycin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-06-18
    Completion
    2021-05-19
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Bacterial Skin and Skin Structure Infection
    InterventionXydalba; vancomycin, teicoplanin or daptomycin
    PhaseNot recorded
    Registry statusCompleted

  • Description of Eosinophilic Pneumonia in BJI/PJI Treated by Daptomycin

    NCT04414137 · start 2019-02-19

    Registered record
    Registry ID
    NCT04414137
    Conditions
    Dactinomycin Adverse Reaction; Bone and Joint Infection
    Interventions
    Description of eosinophilic pneumonia due to daptomycine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-02-19
    Completion
    2021-09-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDactinomycin Adverse Reaction; Bone and Joint Infection
    InterventionDescription of eosinophilic pneumonia due to daptomycine
    PhaseNot recorded
    Registry statusUnknown

  • Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

    NCT03138733 · start 2018-08-26

    Registered record
    Registry ID
    NCT03138733
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Ceftobiprole medocaril; Daptomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-08-26
    Completion
    2022-03-11
    Enrolment
    390

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionCeftobiprole medocaril; Daptomycin
    PhasePhase 3
    Registry statusCompleted

  • Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis

    NCT03480191 · start 2018-06-07

    Registered record
    Registry ID
    NCT03480191
    Conditions
    Pneumococcal Meningitis
    Interventions
    Daptomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-06-07
    Completion
    2024-08-21
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumococcal Meningitis
    InterventionDaptomycin
    PhasePhase 2
    Registry statusCompleted

  • Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections

    NCT03426761 · start 2018-01-25

    Registered record
    Registry ID
    NCT03426761
    Conditions
    Bone Infection; Osteomyelitis; Septic Arthritis; Joint Infection; Prosthetic Joint Infection
    Interventions
    Dalbavancin; Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-01-25
    Completion
    2022-12-31
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone Infection; Osteomyelitis; Septic Arthritis; Joint Infection +1 more
    InterventionDalbavancin; Vancomycin
    PhasePhase 4
    Registry statusCompleted

  • IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB

    NCT02660346 · start 2015-11

    Registered record
    Registry ID
    NCT02660346
    Conditions
    Bacteremia
    Interventions
    Daptomycin; Vancomycin; Ceftaroline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-11
    Completion
    2018-01-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteremia
    InterventionDaptomycin; Vancomycin; Ceftaroline
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetic Variability of Daptomycin During Prolonged Therapy for Bone and Joint Infections

    NCT03209921 · start 2015-05

    Registered record
    Registry ID
    NCT03209921
    Conditions
    Bone and Joint Infection; Patient Treated by Daptomycin
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-05
    Completion
    2015-09
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone and Joint Infection; Patient Treated by Daptomycin
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted